You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Pudendal neuromodulation for incontinence and sphincter dyssynergia after spinal injury

    SBC: Dignify Therapeutics LLC            Topic: 106

    Spinal cord injurySCIfrequently produces severelife long bladder and bowel dysfunction that result in urinary and fecal incontinenceas well as sphincter dyssynergia that causes urinary retention and fecal impactionCurrent standard of care for incontinence consists of adult diaperswhile bladder and bowel voiding require multiple times daily catheterization of the bladder and regular digital extract ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. MARCKS: A novel therapeutic target in uveitis

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NEI

    ABSTRACT Uveitisthe most common form of intraocular inflammationaccounts forof preventable blindness in the USTreatment options are limited to cortiscosteroids and or immunosuppressantsbut both of these therapies show limited efficacy and are associated with numerous adverse and potentially serious side effectsNew therapeutic targets leading to effective and safe treatments are urgently requiredA ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: Lyst Therapeutics LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility

    SBC: Anelleo, Inc.            Topic: NICHD

    Infertility is a global health problemand in the USmillion women are treated for infertility every yearThere is a strong need to promote patient friendly methods for progesterone supplementation in assisted reproductive technologyARTIntravaginal rings are well tolerated by womenare efficacious for contraception and hormone replacement therapyhave high patient complianceand are now in development f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Improving the Oral Bioavailability and In vivo Efficacy of a Novel TAK1 Inhibitor Targeting Rheumatoid Arthritis

    SBC: EYDIS BIO, INC.            Topic: NIAMS

    Project SummaryAbstract Rheumatoid arthritisRAis a chronic inflammatory disease in which hyperactivated immune cells induce maladaptive persistent inflammation in the jointsleading to synovial inflammation and bone remodelingIn the USRA currently affects roughlyof the population and carries a total annual societal cost burden of approximately $billionIn RAsustained elevations of pro inflammatory c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government